Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud Veterinary Practice Management & Client Engagement
Cloud vet practice management acquired by IDEXX; Auckland New Zealand; 5,000+ clinics in US, Australia, NZ, and UK; covers patient check-in through invoicing and end-of-day reconciliation.
ezyVet is a cloud-based veterinary practice management and client engagement platform that provides veterinary clinics with patient records, scheduling, invoicing, billing, client communication, and analytics in a fully browser-based system, headquartered in Auckland, New Zealand and acquired by IDEXX Laboratories — the global veterinary diagnostics leader — in 2021 to extend IDEXX's software platform capabilities alongside its diagnostic products. ezyVet serves more than 5,000 veterinary clinics globally with particular strength in the United States, Australia, New Zealand, and the United Kingdom.\n\nezyVet's platform provides a comprehensive clinical workflow covering patient check-in, consultation and treatment planning, prescription management, invoicing, and end-of-day reconciliation. The two-way client communication features include automated appointment reminders via SMS and email, post-visit summaries, and a client portal where pet owners can access records and request appointments. Deep integration with IDEXX's diagnostic products — including in-clinic analyzers, reference laboratory services, and imaging systems — allows results to flow directly into patient records, providing a significant competitive advantage now that IDEXX owns the platform.\n\nAs an IDEXX-owned platform, ezyVet benefits from IDEXX's global distribution network, integration with IDEXX's full diagnostics portfolio, and the ability to bundle software with diagnostic equipment and service agreements. ezyVet competes with Provet Cloud, Vetspire, Digitail, and the legacy IDEXX Cornerstone platform in the veterinary software market. IDEXX's ownership creates both an advantage (deep diagnostics integration) and a competitive consideration for clinics that use non-IDEXX diagnostic products.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.